All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Join our
Treating classical Hodgkin lymphoma: Spotlight on targeted therapies
with Gilles Salles, Paul Bröckelmann, and Ann S. LaCasce
Saturday, November 2, 2024
8:50-9:50 CET
This independent educational activity is sponsored by Takeda. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene and Roche, and supported through educational grants from Bristol Myers Squibb, Ipsen Biopharmaceuticals, Pfizer, and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. View funders.
For every treatment team and researcher to have instant access to expert opinions and the latest evidence-based information in lymphoma and CLL, to aid in treatment decisions and improve the lives of patients with lymphoma globally.
The Lymphoma Hub is the solution for a time-stretched HCP to easily access impactful information that expedites learning and empowers their treatment decisions. Informed by patients, curated by world leaders and endorsed by expert societies the Lymphoma Hub supports HCPs worldwide.
The Lymphoma Hub was founded in partnership with the European Lymphoma Institute (ELI) in 2014. ELI is comprised of a network of top European specialists in the field of lymphoma who are dedicated to research, training, and education. Together they look to define strategies to analyze and characterize lymphoma, common diagnostic procedures, and therapeutic standards, as well as to facilitate clinical and fundamental research. This leads to the advancement of lymphoma research, and works to guarantee equal access for all patients to the best possible care.
The European LeukemiaNet (ELN) is a publicly funded network of excellence, where clinicians and scientists improve therapy options for patients with leukemia worldwide. Together, they look to define strategies to improve leukemia characterization, its common diagnostic procedures and therapeutic standards, as well as to facilitate clinical and fundamental research. This approach results in the advancement of leukemia research, and it supports equal access for all patients to the best possible care.
Independent medical education (IME), informed by patients, curated by world leaders, endorsed by expert societies. SES supports healthcare professionals and patients worldwide with up-to-date, accessible, and impactful educational content. Our hubs tackle information overload, providing a comprehensive central resource for healthcare professionals (HCPs) in specific disease areas that keep them up-to-date with the latest therapeutic news and world leading opinions. Endorsed by expert societies, and a member of the gCMEp, our platforms ensure credibility and trust. By identifying and filling knowledge gaps in easily digestible formats, we facilitate continuous learning, leading to improved patient outcomes.
The Lymphoma Hub is brought to you by Scientific Education Support (SES). SES loves nothing more than building communities and networks to facilitate education through collaboration, in order to enable access to the latest support and treatment options for patients. The SES team takes care of the everyday management, content generation, and uploads onto the Lymphoma Hub, assisting the steering committees in keeping the site as up-to-date as possible.